BioPorto Diagnostics


Market CapDKK884m

Last Close DKK3.3

BioPorto Diagnostics is a diagnostic company focused on the development and commercialisation of biomarker-based assays. The company’s portfolio includes The NGAL Test, for the prediction of acute kidney injury, and an extensive antibody library.

More BioPorto Diagnostics content >

Investment summary

BioPorto’s lead strategic goal is development of a test for acute kidney injury (AKI) using the biomarker NGAL. The company is gathering more data for its paediatric urine NGAL 510(k) and expects to complete the clinical trial by the end of 2021, following encouraging interim data. For adults using plasma NGAL, the 510(k) will be submitted to the FDA after the submission for paediatric. The NGAL Test is commercially available for research purposes in the United States and has been CE marked in Europe. BioPorto also sells a series of other antibodies, ELISA kits and related biologics.

Y/E Dec
Revenue (DKKm)
EPS (ore)
P/E (x)
P/CF (x)
2019A 26.6 (68.3) (71.1) (39.16) N/A N/A
2020A 23.2 (54.3) (61.5) (28.10) N/A N/A
2021E 32.2 (71.4) (74.5) (25.21) N/A N/A
2022E 179.3 68.3 65.2 21.00 15.7 N/A
Industry outlook

The current standard of care for detecting AKI is serum creatinine, which can take 24 hours or more to detect AKI and can only do so after significant kidney damage. NGAL promises to provide a quicker and more reliable test, allowing early intervention to preserve kidney function.

Last updated on 21/09/2021
Content on BioPorto Diagnostics
Bioporto – executive interview
Healthcare | Edison TV | 19 March 2021
View more
Register to receive research on BioPorto Diagnostics as it is published
Share price graph
Balance sheet
Forecast net cash (DKKm) 51.1
Forecast gearing ratio (%) N/A
Price performance
Actual 5.8 (8.2) 33.2
Relative* 8.7 (16.6) (2.4)
52-week high/low DKK7.8/DKK2.6
*% relative to local index
Key management
Thomas Magnussen Chairman
Peter Mørch Eriksen CEO
Ole Larsen CFO
Jan Kuhlmann Andersen COO